7th Annual Spring to Life Conference on Lung Cancer

Albany, NY | April 18, 2020




April 18, 2020
Albany Marriott Hotel
189 Wolf Road
Albany, NY 12205


Please click here if you would like to be notified when registration is open. We hope to see you in 2020!
S2L | Registration HCP


Spring to LifeTM Conference on Immuno-Oncology: Harnessing the Power of our Immune System in Cancer Therapy is an accredited educational program developed by New York Oncology Hematology (NYOH), in collaboration with the Center for Emergency Medical Education (CEME), the Leukemia & Lymphoma Society, and a panel of expert faculty from the academic, research, and community practice settings.


With programming for both healthcare professionals and the community, the goal of this 1-day activity is to bring together cancer care providers and members of the community, including patients, survivors, their family, and caregivers, to gain an up-to-date understanding of blood cancers, including ongoing research, clinical management, and emerging therapies. The program also provides perspectives on the impact of cancer on the lives of patients and families. The 2019 conference goal is to inform, update, and improve practitioners’ understanding of existing and emerging immunologic therapies for cancer. The theme of the afternoon patient program is Hopefulness During Change, Aging, Illness and Loss.


The target audience for this conference is hematologists, oncologists, nurse practitioners, physician assistants, oncology nurses, family, and primary care practitioners, allied health professionals, and any other interested cancer care providers. Healthcare professionals are welcome and encouraged to participate in the afternoon patient-centered sessions.

Healthcare professionals are welcome and encouraged to participate in the afternoon patient-centered sessions.



After completing this activity, participants should be better prepared to:
  • Review the basic science of the immune system interactions with cancer
  • Discuss the existing and emerging data on checkpoint inhibition therapy
  • Evaluate a variety of historical, contemporary and emerging immunotherapy approaches through the paradigm of cutaneous melanoma
  • Describe the evolving paradigms and data on allogeneic hematopoietic stem cell transplantation
  • Review the data on current and emerging Chimeric Antigen Receptor T cell (CAR-T) and other cellular therapy constructs

This Activity Is Planned By myMedEd, Inc.


Accredited Provider: